World of Health

In the last two decades mouth cancer has risen by 50%, which is accredited to the increase in the spread of HPV (human papilloma virus).  HPV is already responsible for around 80% of all cervical cancer cases, which has prompted the new vaccine that is administered as young as 12 to females to prevent infection later in life by the disease.

The study claims that the reason that mouth cancer may be on the rise is because HPV is transmitted via oral sex.  Consideration should thus be given to extending the vaccination program against HPV to include boys as well as girls.

Lead author of the study from the Coventry University Hospital, Hisham Mehanna, stated that HPV related mouth cancer is a new disease in terms of other cancers that are caused in the mouth.

For the most part, throat and mouth cancers are associated with excessive drinking and smoking and usually only affect older people out of which a third usually die within two years.

On the other hand, mouth cancers caused by HPV have a larger survival rate with about 80% of those diagnosed still living two years later dependent on which stage the cancer was in when discovered.

The type of cancer caused by HPV is oropharyngeal, which is a tumour that develops near the rear of the mouth at the connection with the throat.

The research found that those who had a past of six or more different sexual partners had a 25% higher risk of developing cancer in their mouth.

The UK smoking ban was introduced four years ago, with the aim of making life so difficult for smokers to encourage them to quit. As we approach this year’s “No Smoking Day’, what is evidence to suggest whether this has really worked.

The rate if giving up seems to have fallen. Statistics from the NHS Information Centre show that 19,473 fewer smokers had managed to kick the habit in the latest year compared with 2007/08. The number of pregnant women who successfully stopped smoking also dropped, falling 12% to 8,641. However, compared with the year the smoking ban was introduced in 2006/07, the latest data still shows 71,000 more people tried to quit over the past year and 17,000 more people were successful.

This year’s ‘No Smoking Day’ campaign theme, Break free, helps, acknowledges that No Smoking Day is the time for smokers to break free from their smoking habit and escape their chains of addiction. The following video provides some useful assistance with some top tips on stopping smoking.

A recent report by The james Whale Fund for Kidney Cancer states the UK’s death rate is ’still around 6% higher than the European average’. This finding is set alongside the fact that spending on cancer medicines in the UK is only about 60% of that in other advanced European countries.

The relatively poor take-up of new treatments in the UK is one of the reasons listed in the report as ‘contributing to the higher death rate’. The Cancer Patient Support Group at The James Whale Fund for Kidney Cancer last week launched an online petition at No. 10 Downing Street calling for a review of the current system of NICE appraising newly licensed and approved Cancer drugs.

http://petitions.number10.gov.uk/NewCancerDrugs/

The news about poor uptake of cancer drugs comes as no surprise to kidney cancer patients from the James Whale Fund for Kidney Cancer; only last week kidney cancer patients received the devastating news that NICE have issued preliminary guidance to the NHS rejecting everolimus (trade name Afinitor & manufactured by Novartis) a new and innovative cancer drug for the second line treatment of advanced kidney cancer.

This comes despite NICE admitting “……..evidence implies that this treatment is clinically effective”.

This is just one example of the dire situation facing many cancer patients in the UK today. No matter what the cancer is, the poor uptake by NICE of cancer treatments is leaving the UK lagging far behind in survival rates.

Rose Woodward & Julia Black who work together helping cancer patients who have been refused funding for cancer treatments at The James Whale Fund for Kidney Cancer stated:

“The NICE decision means many of our UK kidney cancer patients will go without effective drugs, patients cannot afford to buy these drugs themselves and will die prematurely compared to the rest of the world. That is just not acceptable.”

For more information about The James Whale Fund for Kidney Cancer visit www.jameswhalefund.org

The National Institute for Health and Clinical Excellence (NICE) ruled the drug Everolimus (Afinitor) too expensive to fund despite the fact that it’s a proven life prolonging drug for kidney cancer patients. This is especially pertinent to kidney cancer patients as it’s a type of cancer that is very difficult to treat. It cannot be treated with chemotherapy or radiation. Once kidney cancer spreads, then these medications are the only hope left for most of these patients. Clinicians and nurses have only one drug with which to try to help those patients facing a terminal diagnosis. Kidney cancer patients desperately need a second treatment option so that clinicians can offer some hope and comfort to both patients and families trying to come to terms with this devastating disease.

Rose Woodward, Head of Patient Support at the James Whale Fund for Kidney Cancer, said “Kidney cancer patients have seen so much money go into the NHS in the past 10 years – so many initiatives, so many targets, so many programmes. What we would really like is for every politician, regardless of what party they belong to, to get together with the Department of Health Mandarins and to listen. Then act on what patients and their families are saying. We want cancer care in the UK to rival the best in the world – it is ironic and very sad that on a day when Gordon Brown promises one to one care for cancer patients NICE issue a statement denying clinicians the chance to offer Everolimus (Afinitor), a clinically effective “end of life” treatment for kidney cancer patients”.

Dr Thomas Powles Trustee and Medical Advisor of the James Whale Fund for Kidney Cancer: “Everolimus (Afinitor) offers kidney cancer patients a clear clinical benefit and is a breakthrough in treating the disease. Its recent rejection by NICE is based on economic rather than clinical grounds. It leaves kidney cancer patients in the UK at a major disadvantage compared to the rest of Europe and the United States, as there are no other options available for this group of patients. This decision is very out of touch with the patient’s needs”.

The Fund believes that patients with kidney cancer should not be penalised because they suffer from a rare cancer; the NHS should ensure all cancer patients are treated fairly and equally. James Whale, founder and chairman of the James Whale Fund and a kidney cancer survivor says “As someone who has been directly affected by kidney cancer, this decision is scandalous as NICE agrees Everolimus (Afinitor) is clinically effective as a second line treatment for kidney cancer. I find it incomprehensible that the government spends more on NICE decision making committees than it would spend if they gave kidney cancer patients this drug.

The NICE decision means our UK kidney cancer patients will die prematurely compared to the rest of the world. This is so obviously a decision based on lack of funding because NICE accepts the drug works. It’s a cruel decision that will cause kidney cancer patients and families huge distress at a time they should be looked after by the NHS and not just abandoned.

About the Fund: The James Whale Fund is the UK’s leading kidney cancer charity and was set up in 2006 by the broadcaster James Whale who lost a kidney to cancer in the year 2000. Today James continues to lead a full and busy life, as do the majority of people who are diagnosed and treated early. Every year almost 7000 people in the UK learn that they have kidney cancer; that’s over 16 people a day. And yet the condition – the eigth most common cancer among men – rarely attracts much public attention. Our mission at the James Whale Fund is to try and change that.

For more information about The James Whale Fund for Kidney Cancer please visit www.jameswhalefund.org

Scientists have proposed that those with a high level of Vitamin D in their blood are less likely to end up with bowel cancer, versus those with lower levels.

The study, which was published in the British medical Journal, found that those with a high level had a 40% less risk of developing the cancer.

The study looked at 1,248 people that were diagnosed with bowel cancer, and a control group of 1,248.

Scientists carried out the research at the International Agency for Research on Cancer in France and at the London Imperial College.

The results of the study were released following increased concern that rickets is occurring more often because of vitamin D deficiency.

Vitamin D is usually found in sunlight but can also be consumed in a small variety of foods such as cod liver oil and oily fish.

The research team stated though that although a lack of Vitamin D may heighten the risk of bowel cancer there is still not any proof that Vitamin D supplements will reduce the risk.  Scientists stated instead that more studies will need to be completed first.

Science programme manager for World Cancer Research Fund, Dr Panagiota Mitrou, stated that the study was the largest of its type concerning bowel cancer and that there is a growing amount of evidence that suggests Vitamin D and bowel cancer are linked.

Mitrou continued to say the next step is to complete further clinical studies to ascertain if Vitamin D supplements can help lower the risk of developing bowel cancer.